These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 26485680)
1. Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis. Luedike P; Rammos C; Pohl J; Heisler M; Totzeck M; Kleophas W; Hetzel GR; Kelm M; Hendgen-Cotta U; Rassaf T PLoS One; 2015; 10(10):e0140215. PubMed ID: 26485680 [TBL] [Abstract][Full Text] [Related]
2. Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease. Rammos C; Hendgen-Cotta UB; Sobierajski J; Adamczyk S; Hetzel GR; Kleophas W; Dellanna F; Kelm M; Rassaf T Int J Cardiol; 2013 Oct; 168(6):5249-56. PubMed ID: 23978362 [TBL] [Abstract][Full Text] [Related]
3. Expressions of macrophage migration inhibitory factor in patients with chronic kidney disease. Liu Y; Zhang X; Liu G; Huang J; Pan Y; Hu Z Niger J Clin Pract; 2016; 19(6):778-783. PubMed ID: 27811451 [TBL] [Abstract][Full Text] [Related]
4. MIF reflects tissue damage rather than inflammation in post-cardiac arrest syndrome in a real life cohort. Pohl J; Rammos C; Totzeck M; Stock P; Kelm M; Rassaf T; Luedike P Resuscitation; 2016 Mar; 100():32-7. PubMed ID: 26784134 [TBL] [Abstract][Full Text] [Related]
5. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Müller II; Müller KA; Karathanos A; Schönleber H; Rath D; Vogel S; Chatterjee M; Schmid M; Haas M; Seizer P; Langer H; Schaeffeler E; Schwab M; Gawaz M; Geisler T Atherosclerosis; 2014 Dec; 237(2):426-32. PubMed ID: 25463068 [TBL] [Abstract][Full Text] [Related]
6. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease. Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549 [TBL] [Abstract][Full Text] [Related]
8. Positive association between plasma levels of oxidized low-density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic end-stage renal disease. Kitabayashi C; Naruko T; Sugioka K; Yunoki K; Nakagawa M; Inaba M; Ohsawa M; Konishi Y; Imanishi M; Inoue T; Itabe H; Yoshiyama M; Haze K; Becker AE; Ueda M Hemodial Int; 2013 Oct; 17(4):557-67. PubMed ID: 23627905 [TBL] [Abstract][Full Text] [Related]
9. High Plasma Levels of Gremlin-1 and Macrophage Migration Inhibitory Factor, but Not Their Ratio, Indicate an Increased Risk for Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. Müller KA; Rath D; Schmid M; Schoenleber H; Gawaz M; Geisler T; Müller II Clin Cardiol; 2016 Apr; 39(4):201-6. PubMed ID: 27101443 [TBL] [Abstract][Full Text] [Related]
11. Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation. Stefaniak J; Schiefer J; Miller EJ; Krenn CG; Baron DM; Faybik P Liver Transpl; 2015 May; 21(5):662-9. PubMed ID: 25762421 [TBL] [Abstract][Full Text] [Related]
12. The differences of asymmetric dimethylarginine removal by different dialysis treatments. Zhang DL; Liu J; Liu S; Zhang Y; Liu WH Ren Fail; 2010; 32(8):935-40. PubMed ID: 20722560 [TBL] [Abstract][Full Text] [Related]
13. Serum macrophage migration inhibitory factor levels are associated with angiographically complex coronary lesions in patients with coronary artery disease. Hao Y; Yi SL; Zhong JQ Genet Test Mol Biomarkers; 2015 Oct; 19(10):556-60. PubMed ID: 26263432 [TBL] [Abstract][Full Text] [Related]
14. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. El-Shehaby AM; El-Khatib MM; Battah AA; Roshdy AR Scand J Clin Lab Invest; 2010 Oct; 70(6):421-7. PubMed ID: 20645679 [TBL] [Abstract][Full Text] [Related]
15. Circulating macrophage migration inhibitory factor (MIF) in patients with heart failure. Luedike P; Alatzides G; Papathanasiou M; Heisler M; Pohl J; Lehmann N; Rassaf T Cytokine; 2018 Oct; 110():104-109. PubMed ID: 29723777 [TBL] [Abstract][Full Text] [Related]
16. Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial Ischemia. Fan F; Fang L; Moore XL; Xie X; Du XJ; White DA; O'Brien J; Thomson H; Wang J; Schneider HG; Ellims A; Barber TW; Dart AM J Am Heart Assoc; 2016 Jun; 5(7):. PubMed ID: 27364992 [TBL] [Abstract][Full Text] [Related]
17. Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Wang D; Luo L; Chen W; Chen LZ; Zeng WT; Li W; Huang XH Oncol Rep; 2014 Mar; 31(3):1199-204. PubMed ID: 24366206 [TBL] [Abstract][Full Text] [Related]
18. Macrophage migration inhibitory factor (MIF) and manganese superoxide dismutase (MnSOD) as early predictors for survival in patients with severe sepsis or septic shock. Brenner T; Hofer S; Rosenhagen C; Steppan J; Lichtenstern C; Weitz J; Bruckner T; Lukic IK; Martin E; Bierhaus A; Hoffmann U; Weigand MA J Surg Res; 2010 Nov; 164(1):e163-71. PubMed ID: 20863520 [TBL] [Abstract][Full Text] [Related]
19. A polymorphism in the macrophage migration inhibitory factor promoter is associated with bronchopulmonary dysplasia. Prencipe G; Auriti C; Inglese R; Devito R; Ronchetti MP; Seganti G; Ravà L; Orzalesi M; De Benedetti F Pediatr Res; 2011 Feb; 69(2):142-7. PubMed ID: 21045753 [TBL] [Abstract][Full Text] [Related]
20. Correlation between Plasma Macrophage Migration Inhibitory Factor Levels and Long-Term Prognosis in Patients with Acute Myocardial Infarction Complicated with Diabetes. Yu H; Wang X; Deng X; Zhang Y; Gao W Mediators Inflamm; 2019; 2019():8276180. PubMed ID: 30983881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]